Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
ESMO 2016 prostate cancer highlights

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.10.16
Views: 3961
Rating:

Dr Eleni Efstathiou, Prof Karim Fizazi, Dr Chris Parker

In this roundtable discussion, chaired by Dr Eleni Efstathiou (MD Anderson Cancer Center, Houston, USA) for ecancertv, experts Prof Karim Fizazi (Cancer Medicine at the Institut Gustave Roussy, Villejuif, France), and Dr Chris Parker (The Royal Marsden, London, UK) highlight and debate advances in prostate cancer from the ESMO 2016 conference.

Our clinical experts share their thoughts on some of the clinical practice changing data overall from ESMO 2016 and debate the more controversial aspects of the ESMO prostate cancer data.

One of the most widely discussed conversations at the congress was how to treat patents with low volume disease. The subgroup analysis of the CHAARTED data indicate that there was no overall survival data for this group of patients. However the panel discuss the bigger picture and how the meta-analysis data may potentially differ and indicate a different clinical treatment strategy.

The panel also discuss whether PTEN loss is a predictive biomarker with the AKT inhibitor ipatsertib when combined with abiraterone acetate. The study indicates that PTEN loss looks like a promising predictive biomarker for mCRPC and warrants further development of Ipat to select patients with PTEN loss and improve clinical outcomes.

Other highlights include the AFFINITY results, KEYNOTE-028 data and the future of BRCA testing for prostate cancer patients.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceuticals (A Johnson & Johnson Company).

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation